Zydelig?

Zydelig is the brand name for the drug duvelisib.

What it is used for
- Duvelisib is a PI3K inhibitor used in adults with certain relapsed or refractory B-cell blood cancers:
- Follicular lymphoma (FL) after at least two prior systemic therapies
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies
- It is typically given when other treatments have not worked or are no longer effective.

How it works
- It blocks PI3K enzymes (specifically PI3K-δ and PI3K-γ) involved in signaling for B-cell growth and survival, helping to slow or stop cancer cell growth.

How it’s taken
- An oral capsule, usually taken twice daily with food.
- Dose and duration are determined by a doctor and may be adjusted for side effects.

Common side effects
- Diarrhea or colitis, nausea
- Rash
- Fatigue, decreased appetite
- Elevations in liver enzymes
- Infections, fever

Serious (important) risks
- Severe immune-mediated toxicities: liver injury (hepatotoxicity), colitis/diarrhea, pneumonitis
- Serious infections (including pneumonia, sepsis)
- Neutropenia (low white blood cell count)
- Other potential serious events and fatalities have been reported
- Because of these risks, Zydelig is available under a restricted program (REMS) and requires careful monitoring

Important safety and use notes
- Not all patients are candidates; benefits must be weighed against risks
- Avoid if you have an active severe infection
- Tell your doctor about all medications you take, since duvelisib is metabolized by CYP3A4; strong CYP3A inhibitors or inducers can affect its levels
- Pregnancy and breastfeeding: avoid; use effective contraception
- Regular monitoring is needed (blood counts, liver enzymes, signs of infection or inflammation)
- If you develop severe diarrhea, abdominal pain, fever, trouble breathing, or unusual bleeding, contact your healthcare provider promptly

If you’d like, I can tailor this to your situation (e.g., if you’re considering treatment, want dosing specifics, or need details on monitoring and REMS). Also I can provide a source with the current labeling.